Endovascular Treatment of Posterior Circulation Saccular Aneurysms With the p64 Flow Modulation Device: Mid-and Long-Term Results in 54 Aneurysms From a Single Center

Victoria Hellstern1*, Marta Aguilar-Pérez1, Elina Henkes1, Carmen Serna-Candel1, Christina Wendl2, Hansjörg Bätzner3, Oliver Ganslandt4 and Hans Henkes1,5

1 Neuroradiologische Klinik, Kopf- und Neurozentrum, Klinikum Stuttgart, Stuttgart, Germany, 2 Institut für Röntgendiagnostik, Zentrum für Neuroradiologie, Universitätsklinikum Regensburg, Regensburg, Germany, 3 Neurologische Klinik, Neurozentrum, Klinikum Stuttgart, Stuttgart, Germany, 4 Neurochirurgische Klinik, Neurozentrum, Klinikum Stuttgart, Stuttgart, Germany, 5 Medizinische Fakultät der Universität Duisburg-Essen, Essen, Germany

Objective: Flow diverter (FD) stents have become one of the most common tools for treating intracranial aneurysms; however, their role in treating posterior circulation aneurysms is still discussed with controversy. In this study, we evaluated the safety and effectiveness of p64 FD for the treatment of saccular, unruptured aneurysms in the posterior circulation over a long-term follow-up period in a single center.

Methods: From our prospectively maintained database, we retrospectively identified patients who underwent treatment of an intracranial saccular aneurysm arising from the posterior circulation with ≥ 1 p64 FD implanted or attempted between October 2012 and December 2019. Aneurysms could have been treated with prior or concomitant saccular treatment (e.g., coiling, intra-aneurysmal flow diversion). Aneurysms with parent vessel implants other than p64, fusiform aneurysms, and dissections were excluded. Peri- and postprocedural complications, clinical outcome, and clinical and angiographic follow-up results were evaluated.

Results: In total, 54 patients (45 female, 9 male; mean age 55.1 years) with 54 intracranial aneurysms met the inclusion criteria. In 51 cases (94.4%), one p64 was implanted; in 2 cases (3.7%), two p64s were implanted; in one case, deployment of the p64 was not feasible. Procedural complications occurred in 3.7% and postprocedural complications in 9.3%, respectively. Hemorrhagic complications occurred in 2/54 patients (3.7%), thereof one fatal parenchymal hemorrhage. Ischemic complications were observed in 5/54 patients (9.3%). Early, mid-term, and long-term angiographic follow-up examinations showed complete or near-complete aneurysm occlusion, defined according to the O’Kelly–Marotta (OKM) scale as OKM C + D in 56, 75.6, and 82.9%, respectively. Asymptomatic side vessel occlusions occurred in 3.8%, each during the first follow-up.
INTRODUCTION

Flow diverter (FD) implantation has become one of the most common tools for treating intracranial aneurysms (IAs). In the last years, the number of available FDs has increased continuously. One of these FDs is the p64 FD (phenox, Bochum, Germany). Its unique feature is that it can be deployed entirely and reshaped due to its mechanical detachment system allowing for potentially necessary repositioning. Several published studies have reported the long-term efficacy of the p64 (1–3). However, these studies have focused mainly or exclusively on aneurysms in the anterior circulation. There is only limited data for treating aneurysms with the p64 in the posterior circulation.

Furthermore, FD in the posterior circulation is still discussed more controversially due to higher rates of ischemic complications and morbidity and mortality (4–6).

In the present study, we report the experience of treating intracranial saccular unruptured aneurysms arising from the posterior circulation endovascularly with the p64 FD. To the best of our knowledge, this is the most extensive study to report data for saccular aneurysms in the posterior circulation treated exclusively with the p64 FD.

METHODS

Device Description

The p64 Flow Modulation Device is braided from 64 nitinol wires and two platinum wires wrapped around opposing nitinol wires for visibility under x-ray fluoroscopy. At the proximal end, the 64 wires form 8 bundles, each carrying a radiopaque marker. The unique feature of the p64 is that after full deployment, it is entirely resheatable and repositionable due to its mechanical detachment. It is delivered via a 0.027-inch inner diameter microcatheter.

Patient Population

We retrospectively reviewed our prospectively maintained database to identify all patients with intracranial saccular unruptured aneurysms in the posterior circulation treated with at least one p64 FD between October 2012 and December 2019. Inclusion criteria for this series were all aneurysms treated endovascularly with p64 implantation only or with p64 and simultaneous or prior coiling. Only patients with unruptured aneurysms or past the acute stage of SAH (>30 days) were included. Fusiform, dissecting, or blister-like aneurysms, as well as dolicho-ectatic basilar artery aneurysms, were excluded. Aneurysms treated with other parent vessel implants such as other FDs or stents were also excluded. We recorded demographic data, anatomical features, location of the aneurysm, procedural and post-procedural complications, and clinical and angiographic outcomes according to the latest available follow-up for each of these patients.

Conclusions: The implantation of a p64 FD is a safe and effective device for endovascular treatment of posterior circulation saccular aneurysms with a high success rate and low morbidity-mortality.

Keywords: p64, posterior circulation aneurysms, flow diversion, unruptured aneurysm, saccular aneurysm

Endovascular Procedure

In each case, patients had given written informed consent at least 24 hours before the procedure after being informed about the intended treatment and potential alternatives.

All treatments were performed under general anesthesia using bi-plane digital subtraction angiography (DSA) units (Axiom Artis, Siemens, Erlangen, Germany). A 6F short sheath with a 6F guiding catheter was used via right-sided femoral access as the standard approach. In cases with severe vessel elongation and the need for an intermediate catheter, an 8F right femoral approach was used. Heparin was administered intravenously immediately after groin puncture (usually 3,000 IU unfractionated heparin IV). All flushing solutions, including the guiding catheters and microcatheters, were heparinized (5,000 IU unfractionated heparin/l).

The p64 was deployed via an Excelsior XT27 (Stryker Neurovascular, Kalamazoo, MI, USA) microcatheter. The diameter and length of the p64 were chosen based on intraprocedural 2D and 3D calibrated measurements of the diameter of the parent artery, the distance between the proximal and distal landing zones, the discrepancy of the diameter between the landing zones, and the aneurysm neck size taking into account potential device foreshortening. Once satisfactory deployment and positioning were achieved, the p64 was mechanically detached.

Medication

All patients received dual antiplatelet therapy (DAPT) with 1 × 100 mg acetylsalicylic acid (ASA) PO daily and either 1 × 75 mg clopidogrel or 2 × 90 mg ticagrelor or 1 × 10 mg prasugrel PO daily for at least five days before treatment. Alternatively, a loading dose of 500 mg ASA and either 600 mg clopidogrel or 180 mg ticagrelor or 30 mg prasugrel 24h before the treatment was given. From 2012 until 2015 the standard approach was DAPT with ASA and clopidogrel and ticagrelor was only used in case of non-responders to clopidogrel. From 2015 on the standard approach was switched to ASA and ticagrelor to avoid issues due to non-responders to clopidogrel and to achieve a stronger DAPT. Prasugrel was given in case of insufficient DAPT under ticagrelor or in case of intolerance to ticagrelor. The response tests of the antiplatelet regime were done with the Multiplate Analyzer (Roche Diagnostics, Mannheim, Germany) and with the Verify Now (Accriva, San Diego, CA, USA). No p64 was implanted unless adequate platelet inhibition was confirmed. Procedural medication consisted of a daily dose of 100 mg ASA and either 1 × 75 mg clopidogrel or 2 × 90 mg
ticagrelor or 1 × 10 mg prasugrel PO daily for at least one year. Then DAPT was stopped and switched to 1 × 100 mg ASA PO daily lifelong. According to our institutional protocol, postmedication in patients with an anticipated increased risk of ischemic complications (e.g., if many perforating arteries were covered with an undersized p64) consisted of 2 × 3,000 IU certoparin s.c. (Mono-Embolex, Mylan Healthcare, Germany), daily for 4–6 weeks after flow diversion treatment. The decision to add heparin to the therapy regimen was made based on the device location in perforator-rich areas and the size of the device in relation to the parent vessel.

Data Collection and Follow-Up
Patency of the parent vessel and distal and side branches and flow characteristics within the flow diverter was assessed angiographically immediately after deployment of the p64 and during follow-ups.

Patients were scheduled for clinical and angiographic follow-up examinations as follows: early follow-up (3–6 months), mid-term follow-up (9–12 months), and long-term follow-up (>24 months). Assessment of the aneurysm occlusion was evaluated according to the O’Kelly-Marotta (OKM) – scale, based on the degree of aneurysm perfusion [7]. Adequate occlusion was defined as OKM C and D. Neurological examinations were performed in the peri-procedural period (<24h), post-procedural period (>24h ≤ 30 days), and during the follow-up (>30 days) by a neurologist or a certified stroke nurse, and recorded using the modified Rankin Scale (mRS) [8]. The clinical sequelae of any complication were classified as “transient neurological deficit,” “permanent minor neurological deficit” (i.e., mRS 1 or 2), “permanent major neurological deficit” (i.e., mRS 3–5) or “death.” [9].

RESULTS
Patient’s Demographics and Aneurysm Characteristics
Between October 2012 and December 2019, a total of 54 patients with 54 aneurysms of the posterior circulation were identified who met the inclusion criteria. There were 45 female patients in our cohort (83 %), and the mean age of the patients was 55.1 years (range 29–76) (Table 1).

The mean aneurysm dome size was 3.6 mm (range 0.8–18 mm). Of the 54 aneurysms treated, 51 (94.6 %) aneurysms were small (<10mm), 3 (5.5%) were large (10–25mm), and 0 (0 %) was giant (>25mm). In 51 cases (94.4%), one p64 was implanted, in 2 cases (3.7%), 2 p64 were implanted, and in one case (1.9%), the deployment of a p64 was not feasible even though two different p64 were tried. The implantation of the p64 was the first procedure in 39 aneurysms (72.2%), whereas the remaining 15 aneurysms (27.8%) had been treated before as follows: coiling n = 12, coils + Medina n = 1, WEB n = 1, microsurgical clipping (n = 1, the attempted clipping failed). In 10 procedures (18.5%), coils were used as additional devices; in one case (1.9%), additional coiling was attempted but failed. Out of the 54 treated patients 17 patients (31.5%) with an anticipated increased risk of ischemic complications were given additional heparin for 4–6 weeks. Three patients still presented symptoms due to perforator ischemia.

The distribution of the location of the aneurysms in the posterior circulation was: basilar artery (BA)-bifurcation n = 10 (18.5%), BA-trunk n = 6 (11.1%), posterior cerebral artery (PCA) n = 3 (5.6%), posterior inferior cerebellar artery (PICA) n = 18 (33.3%), superior cerebellar artery (SCA) n = 14 (25.9%) and vertebral artery (VA) intradural n = 3 (5.6%) (Table 1).

The mean diameter of the distal landing zone was 2.4 mm (range 1.3–4.4mm), and of the proximal landing zone, 3.0 mm (range 1.6–4.2 mm); the mean discrepancy of the diameter between the proximal and distal landing zone was 0.5 mm, ranging from −1.2 to 1.8 mm.

Angiographic Follow-Up
An early follow-up (FU) DSA examination (3–6 months) was available for 50 of the 53 (94.3%) aneurysms in which the implantation of the p64 was successful. The FU was performed after a median of 96 days ranging from 42–379 days. The angiographic findings were as follows: complete aneurysm occlusion (OKM D) was observed in 22 (44 %), and a neck remnant (OKM C) in 6 (12%) aneurysms. For 17 (34%) aneurysms, subtotal aneurysmal filling (OKM B) was found. Five aneurysms (10%) remained unchanged (OKM A). In-stent stenosis was found in 3 patients (6%) thereof two moderate ones (50–75%), and one (2%) was graded severe (>75%). All of the patients mentioned above were asymptomatic. Furthermore, there were 2 (4%) side vessel occlusions observed, both asymptomatic.

A mid-term follow-up (9–12 months) was available in 49/53 aneurysms (92.5 %) after a median of 275 days (range 93–522), showing complete aneurysm occlusion (OKM D) in 31/49 (63.3%), neck remnant (OKM C) in 6 (12.3%) aneurysms, and a sac remnant (OKM B) in 8 (16.3 %) aneurysms. Four (8.2 %) aneurysms remained still unchanged (OKM A). In-stent

| TABLE 1 | Baseline patient demographics and clinical presentation of the study population. |
|-----------------------------|-----------------------------|
| Patients characteristics    |                             |
| Number of patients          | 54                          |
| Gender (m/f)                | 9/45                        |
| Number of aneurysms         | 54                          |
| Previously treated aneurysms| 15/54 (27.8%)               |
| Coiling                     | 12                          |
| Coiling + Medina            | 1                           |
| WEB                         | 1                           |
| Microsurgical clipping (failed) | 1                      |
| Aneurysm location           |                             |
| Basilar artery bifurcation   | 10 (18.5%)                  |
| Basilar artery trunk         | 6 (11.1%)                   |
| Posterior cerebral artery    | 3 (5.6%)                    |
| Posterior inferior cerebellar artery | 18 (33.3%) |
| Superior cerebellar artery  | 14 (25.9%)                  |
| Vertebral artery (V4)        | 3 (5.6%)                    |

| Aneurysm location           |                             |
| Basilar artery bifurcation   | 10 (18.5%)                  |
| Basilar artery trunk         | 6 (11.1%)                   |
| Posterior cerebral artery    | 3 (5.6%)                    |
| Posterior inferior cerebellar artery | 18 (33.3%) |
| Superior cerebellar artery  | 14 (25.9%)                  |
| Vertebral artery (V4)        | 3 (5.6%)                    |

Frontiers in Neurology | www.frontiersin.org 3  July 2021 | Volume 12 | Article 711863
TABLE 2 | Angiographic results and occlusion rates.

| Available FU | 1st FU | 2nd FU | 3rd FU |
|--------------|--------|--------|--------|
| 1st FU       | 50/53  | 49/53  | 41/53  |
| 2nd FU       | 50/53  | 49/53  | 41/53  |
| 3rd FU       | 50/53  | 49/53  | 41/53  |

Occlusion rates OKM C+D

| Location | 1st FU | 2nd FU | 3rd FU |
|----------|--------|--------|--------|
| BA- bifurcation | 71.4% (7/50) | 85.7% (6/7) | 100% (6/6) |
| BA-trunk | 83.3% (5/6) | 100% (6/8) | 100% (6/6) |
| PCA      | 66.7% (2/3) | 100% (3/3) | 100% (2/2) |
| PICA     | 44.4% (8/18) | 62.5% (10/17) | 78.6% (12/15) |
| SCA      | 38.5% (5/13) | 61.5% (8/13) | 63.9% (7/13) |
| V4       | 100% (3/3) | 100% (3/3) | 100% (2/2) |

Side vessel occlusion at FU

- 1st FU: 100%
- 2nd FU: 100%
- 3rd FU: 100%

Complications

Intraprocedural complications occurred in 2 out of the 54 procedures (3.7%). In one patient, the FD dislocated after detachment, causing incomplete coverage of the aneurysmal neck. Therefore, a second FD was placed.

One patient suffered a subarachnoid hemorrhage (SAH) Hunt & Hess II, Fisher 2 due to a suspected microwire perforation and a dissection of the vertebral artery in the V2 segment that was reconstructed with the implantation of 2 Solitaire Stents (Solitaire AB, Medtronic). The implantation of the p64 failed in this patient due to unstable access. Therefore, the aneurysm was treated with partial coiling of the dome, accepting a neck remnant. The clinical outcome of these patients was rated as mRS 3, equivalent to the condition before the treatment.

Postprocedural complications (24h–30d) were observed in 5 patients (9.3%).

A hemorrhagic complication was observed in one patient (1.9%). This patient suffered a fatal hemorrhage on the day of discharge. The other four patients (7.4%) suffered from symptomatic ischemia resulting in permanent deficits in three patients, and transient symptoms in one patient. A delayed complication (>30 days) occurred in one patient (1.9%) who presented with an internuclear ophthalmoplegia (INO) 15 months after the implantation of the p64 (Tables 4, 5).

We did not observe any device-related thromboembolic complications in our series during the procedural and postprocedural period nor any in-stent thrombosis.

Clinical Follow-Up

Clinical deterioration with a permanent worsening of the mRS was reported in 5 of the 54 patients (9.3%) as follows: one fatal hemorrhage (mRS 6, 1.9%), one shift of the mRS from 0 to 2 (1.9%), and 3 patients with a shift from mRS 0 to 1 (5.6%) (Table 3).

Tables 2, 3 show a breakdown of aneurysm occlusion rates and Tables 4, 5 of complication rate.
Hellstern et al.  

**DISCUSSION**

Flow diversion has gained an essential role in treating IAs in the last decade, especially in wide-necked, giant, or fusiform aneurysms. This is even more distinct for the so-called “challenging” aneurysm in the anterior circulation. The implantation of FDs for the treatment of posterior circulation aneurysms remains controversial due to the significantly higher rates of ischemic complications and higher morbidity and mortality that have been reported throughout the literature (4, 6, 10). However, the composition of the respective study populations has to be considered as they did not solely focus on saccular aneurysms but also included giant, fusiform, and dissecting aneurysms. It has been shown that these non-saccular...
aneurysms are especially prone to ischemic complications due to extensive thrombus formation (5, 11). In this series, only saccular aneurysms were included. We observed ischemic complications in 4/54 patients (7.4%), with 1/54 (1.9%) patients suffering a deterioration of the mRS from 0 to >2. According to previously published data, these results confirm that smaller (usually saccular) aneurysms carry a lower risk of ischemic complications (12).

The porosity of the FD is another crucial factor regarding ischemic complications and aneurysm occlusion rates. The porosity is defined as the ratio of metal-free surface area to the entire surface area, and pore density is the number of pores per unit surface. It has been shown that FD with a porosity of 70% achieves a high rate of aneurysm occlusion without affecting the covered branches (13).

The p64 is braided using 64 nitinol wires with a lower porosity of 51–60%, depending on the device size in relation to the parent vessel diameter (14). Lower porosity is supposed to lead to higher occlusion rates but might also be prone to more ischemic complications. Aguilar et al. reported high complete or near-complete occlusion rates of 89.7% at mid-term FU and 94.5% at long-term FU (>24 months) in saccular aneurysms in the anterior circulation in the most extensive study with the p64 from a single center (2). Despite the higher porosity of the p64, they observed similar ischemic complication rates—reported as 4.8% in their study—that have been reported for other FDs such as the Pipeline Embolization Device (PED) (Medtronic, Dublin, Ireland), Silk (Balt Extrusion, Montmorency, France), and Surpass (Stryker Neurovascular, Fremont, CA, USA) (15). As compared to these data, we observed a higher rate of ischemic complication of 9.3% overall in this study, as is to be expected due to the increased vulnerability of the covered perforating arteries of the posterior circulation compared to FD in the anterior circulation. However, there was only one major stroke (1.9%) despite the higher porosity of the p64. In comparison, Bender et al. report major stroke complications of 8% with the PED in the posterior circulation, and Kulcsar et al. report 25% with the SILK FD (12, 16). Despite the higher porosity of p64, the significantly lower rate of severe stroke complications might be attributed to the device’s sizing. We always choose to slightly oversize the FD, avoiding foreshortening and preserving perforating arteries. In addition, for patients with a high risk of perforator stroke, low molecular weight heparin is administered for 4-6 weeks after the FD implantation in addition to the DAPT.

In our analysis concerning occlusion rate, we observed a progressive increase in aneurysm occlusion with complete or near-complete obliteration rate of 56% at 3-month, 75.6% at 9-month, and 82.5% at the last angiographic follow-up. The lowest occlusion rates at the last FU were observed for PICA aneurysms with 78.6% and SCA aneurysms with 63.3%. These low occlusion rates might be because the parent vessels stayed patent in most cases, leading to a reduced flow-diverting
effect by sucking blood from the BA or VA to the respective parent vessel, hence failing to occlude the aneurysm. Similar observations have been reported for fetal PcomA aneurysms.

**TABLE 4 | Complications.**

| Complications                          | No. | Location of the aneurysm | Aneurysm size (width x height in mm) | Device Location of the device | Antiplatet regimen | Platelet-Inhibition at the time of FD-implantation confirmed with Multiplate or Verify Now | Description | Transient vs. permanent | mRS pre | Last mRS |
|----------------------------------------|-----|--------------------------|--------------------------------------|-------------------------------|--------------------|--------------------------------------------------------------------------------------------|-------------|-------------------------|---------|---------|
| Technical                              | 2/54| (3.7%)                  |                                      |                               |                    |                                                                             |             |                         |         |         |
| Hemorrhagic                            | 2/54| (3.7%)                  |                                      |                               |                    |                                                                             |             |                         |         |         |
| Ischemic                               | 5/54| (9.3%)                  |                                      |                               |                    |                                                                             |             |                         |         |         |
| Transient                              | 1/54| (1.9%)                  |                                      |                               |                    |                                                                             |             |                         |         |         |
| Permanent                              | 4/54| (7.4%)                  |                                      |                               |                    |                                                                             |             |                         |         |         |
| Permanent worsening of the mRS         | 5/54| (9.3%)                  |                                      |                               |                    |                                                                             |             |                         |         |         |
| Fatal hemorrhage, mRS 6                | 1/54| (1.9%)                  |                                      |                               |                    |                                                                             |             |                         |         |         |
| Shift from mRS 0 => mRS 1              | 3/54| (5.6%)                  |                                      |                               |                    |                                                                             |             |                         |         |         |
| Shift from mRS 0 => mRS 2              | 1/54| (1.9%)                  |                                      |                               |                    |                                                                             |             |                         |         |         |

mRS, modified Ranking Scale.

**TABLE 5 | Clinically relevant complications overview.**

| No. | Location of the aneurysm | Aneurysm size (width x height in mm) | Device Location of the device | Antiplatet regimen | Platelet-Inhibition at the time of FD-implantation confirmed with Multiplate or Verify Now | Description | Transient vs. permanent | mRS pre | Last mRS |
|-----|--------------------------|--------------------------------------|-------------------------------|--------------------|--------------------------------------------------------------------------------------------|-------------|-------------------------|---------|---------|
| 1   | BA tip                   | 4.2 x 3.4                            | 1 x p64 4/21                 | -                  | 100 mg ASA p.o., 2 x 90 mg ticagrelor p.o.                                             | postprocedural SAH on CCT, transient drowsiness and headache, resolved spontaneously | Transient | 3 | 3   |
| 2   | BA tip                   | 2.9 x 2.2                            | 1 x p64 3/15                | left PCA to BA    | 100 mg ASA p.o., 75 mg Plavix p.o.                                                      | Fatal cerebellar IPH on the day of discharge | Permanent | 1 | 6   |
| 3   | BA trunk                 | 4.6 x 2.3                            | 1 x p64 4.5/15             | BA trunk          | 100 mg ASA p.o., 10 mg prasugrel p.o.                                                  | Bi-lateral pontine perforator infarction with left-sided hemiparesis, dysphagia and dysarthria, at last FU remaining mild dysarthria | Permanent | 0 | 1   |
| 4   | SCA                      | 1.8 x 1.0                            | 1 x p64 3/15                | left PCA to BA    | 100 mg ASA p.o., 75 mg Plavix p.o.                                                      | INO 15 months after treatment, 3 month after stop of DAPT | Permanent | 0 | 1   |
| 5   | PICA                     | 2.3 x 2.1                            | 1 x p64 3.5/15             | right V4 segment  | 100 mg ASA p.o., 75 mg Plavix p.o.                                                      | Scattered diffusion restriction in both cerebellar hemispheres with vertigo, vomiting and dizziness | Transient | 0 | 0   |
| 6   | SCA                      | 1.8 x 2.2                            | 1 x p64 3.5/15             | left PCA to BA    | 100 mg ASA p.o., 75 mg Plavix p.o.                                                      | Bilateral pontine perforator infarction with right-sided hemiparesis | Permanent | 0 | 2   |
| 7   | BA tip                   | 1.5 x 1.2                            | 1 x p64 3/12                | right PCA to BA   | 100 mg ASA p.o., 2 x 90 mg ticagrelor p.o.                                             | Left pontine perforator infarction with discrete finger movement impairment | Permanent | 0 | 1   |

BA, basilar artery; SAH, subarachnoid hemorrhage; CCT, cranial computed tomography; mRS, modified Ranking Scale; IPH, intra-parenchymal hemorrhage; INO, internuclear ophthalmoplegia; SCA, superior cerebellar artery; PICA, posterior inferior cerebellar artery; ASA, acetylsalicylic acid; p.o., per os.
p64 may lead to a higher rate of ischemic complications, which is primarily an essential concern in the posterior circulation. However, an increased number of ischemic complications was not observed in our series, with a total of 5 events (9.3%) consisting of 4 permanent minor neurological deficits (7.4%) and one case (1.9%) of transient neurological symptoms. We observed no permanent major neurological deficit. There was one device-unrelated, treatment-related mortality of 1.9%. This is significantly lower than previous studies reported for FD in one device-unrelated, treatment-related mortality of 1.9%. The observed no permanent major neurological deficit. There was one case (1.9%) of transient neurological symptoms. We consisting of 4 permanent minor neurological deficits (7.4%) not observed in our series, with a total of 5 events (9.3%) in predominantly saccular aneurysms. These numbers are significantly higher than the results from our series with the p64 that carries a supposedly higher risk of ischemic complications. Possible explanations may be the oversizing of the device and the additional use of low molecular weight heparin combined with DAPT during the first 4 to 6 weeks after FD implantation as bridging of the most thrombogenic and, therefore, most vulnerable period after FD implantation.

Of course, DAPT in combination with heparin poses an increased risk for hemorrhagic complications. Hemorrhagic transformation of clinically silent microinfarcts observed after endovascular procedures have been reported as one of the significant drawbacks of FD implantation. Our series report one fatal hemorrhage three days after the p64 implantation, most likely to be attributed to delayed parenchymal hemorrhage due to microischemia. Additionally, this patient had been a hyper-responder for clopidogrel.

The recent introduction of surface-modified, hydrophilic coated FDs such as the p64MW HPC and p48MW HPC (phenox, Bochum, Germany) and the Pipeline Shield (Medtronic, Dublin, Ireland) allows the implantation of FD under single platelet inhibition (SAPT) only.

LIMITATIONS

The limitations of this study include those inherent in a retrospective study, and this study reports the experience of a single center with a single specific flow diverter. Secondly, this study dealt with unruptured, saccular aneurysms of the posterior circulation only, explicitly excluding fusiform, giant, and dissecting aneurysms of the posterior circulation.

CONCLUSION

The p64 is safe and effective for treating intracranial saccular unruptured aneurysms arising from the posterior circulation with acceptable occlusion rates on midterm and long-term follow-ups and low morbi-mortality rate. This represents the most extensive study to date on the use of p64 in saccular posterior circulation aneurysms exclusively.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethikkommission der Landesärztekammer Baden-Württemberg. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

MA-P, EH, CS-C, and VH: data gathering and manuscript preparation. CW, OG, and HB: review and editing. HH: guarantor, overall review, and study design. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Sirakov S, Sirakov A, Bhogal P, Penkov M, Minkin K, Ninov K, et al. The p64 flow diverter—mid-term and long-term results from a single center. Clin Neuroradiol. (2020) 30:471–80. doi: 10.1007/s00062-019-00823-y
2. Aguilar Pérez M, Henkes E, Hellstern V, Serna Candel C, Wendl C, Büzner H, et al. Endovascular treatment of anterior circulation aneurysms with the p64 flow modulation device: mid- and long-term results in 617 aneurysms from a single center. Oper Neurosurg. (2021) 20:355–63. doi: 10.1093/ons/opaa425
3. Briganti F, Leone G, Ugga L, Marsiglia M, Macera A, Manto A. Mid-term and long-term follow-up of intracranial aneurysms treated by the p64 flow modulation device: a multicenter experience. J Neurointerv Surg. (2017) 9:70–6. doi: 10.1136/neurintsurg-2016-012502
4. Wang CB, Shi WW, Zhang G, Lu HC, Ma J. Flow diverter treatment of posterior circulation aneurysms. A meta-analysis. Neuroradiology. (2016) 58:391–400. doi: 10.1007/s00234-016-1649-2
5. Phillips TJ, Wenderoth JD, Phatouros CC, Rice H, Singh TP, Devilliers L, et al. Safety of the pipeline embolization device in treatment of posterior circulation aneurysms. AJNR Am J Neuroradiol. (2012) 33:1225–31. doi: 10.3174/ajnr.A3166
6. Kallmes DF, Handel R, Lopes D, Boccardi E, Bonafé A, Cekirge S. International retrospective study of the pipeline embolization device: a multicenter aneurysm treatment study. AJNR Am J Neuroradiol. (2015) 36:108–15. doi: 10.3174/ajnr.A4111
7. O’Kelly CJ, Krings T, Fiorella D, Marotta TR. A novel grading scale for the angiographic assessment of intracranial aneurysms treated using flow diverting stents. Interw Neuroradiol. (2010) 16:133–7. doi: 10.1177/159101991001600204
8. Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke. (2002) 33:2243–6. doi: 10.1161/01.STR.0000027437.22450.BD
9. Hellstern V, Aguilar-Pérez M, AlMatter M, Bhogal P, Henkes E, Ganslandt O, et al. Microsurgical clipping and endovascular flow diversion of ruptured anterior circulation blood blister-like aneurysms. Interw Neuroradiol. (2018) 24:615–23. doi: 10.1177/1591019918785911
10. Dandapat S, Mendez-Ruiz A, Martinez-Galdamez M, Macho J, Derakhshani S, Foa Torres G, et al. Review of current intracranial aneurysm flow diversion technology and clinical use. J Neurointerv Surg. (2020) 13:54–62. doi: 10.1136/neurintsurg-2020-015877

11. Brinjikji W, Murad MH, Lanzino G, Cloft HJ, Kallmes DF. Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis. Stroke. (2013) 44:442–7. doi: 10.1161/STROKEAHA.112.768151

12. Bender MT, Colby GP, Jiang B, Lin LM, Campos JK, Xu R, et al. Flow diversion of posterior circulation cerebral aneurysms: a single-institution series of 59 cases. Neurosurgery. (2019) 84:206–16. doi: 10.1093/neuros/nyy076

13. Sadasivan C, Cesar L, Seong J, Rakian A, Hao Q, Tio FO, et al. An original flow diversion device for the treatment of intracranial aneurysms: evaluation in the rabbit elastase-induced model. Stroke. (2009) 40:952–8. doi: 10.1161/STROKEAHA.108.533760

14. Fischer S, Aguilar-Pérez M, Henkes E, Kurre W, Ganslandt O, Bäzner H, et al. Initial Experience with p64: A novel mechanically detachable flow diverter for the treatment of intracranial saccular sidewall aneurysms. AJNR Am J Neuroradiol. (2015) 36:2082–9. doi: 10.3174/ajnr.A4420

15. Briganti F, Leone G, Marseglia M, Marinello G, Caranci F, Brunetti A, et al. Endovascular treatment of cerebral aneurysms using flow-diverter devices: a systematic review. Neuroradiol J. (2015) 28:365–75. doi: 10.1177/197140091502803

16. Kulcsár Z, Ernemann U, Wetzel SG, Bock A, Goericike S, Panagiotopoulos V, et al. High-profile flow diverter (silk) implantation in the basilar artery: efficacy in the treatment of aneurysms and the role of the perforators. Stroke. (2010) 41:1690–6. doi: 10.1161/STROKEAHA.110.580308

17. Tsang AC, Fung AM, Tsang FC, Leung GK, Lee R, Liu WM. Failure of flow diverter treatment of intracranial aneurysms related to the fetal-type posterior communicating artery. Neurointervention. (2015) 10:60–6. doi: 10.5469/neuroint.2015.10.2.60

18. Chalouhi N, Tjoumakaris S, Dumont AS, Gonzalez LF, Randazzo C, Starke RM, et al. Treatment of posterior circulation aneurysms with the pipeline embolization device. Neurosurgery. (2013) 72:883–9. doi: 10.1227/NEU.0b013e31828ba984

19. Toth G, Bain M, Hussain MS, Moskowitz S, Masaryk T, Rasmussen P, et al. Post-procedure P2Y12 reaction units value in patients with cerebral aneurysms treated with the Pipeline Embolization Device. J Neurointerv Surg. (2013) 5:iii3–10. doi: 10.1136/neurintsurg-2012-010582

20. Cruz JP, Chow M, O’Kelly C, Marotta B, Spears J, Montanera W, et al. Delayed ipsilateral parenchymal hemorrhage following flow diversion for the treatment of anterior circulation aneurysms. AJNR Am J Neuroradiol. (2012) 33:603–8. doi: 10.3174/ajnr.A3065

21. Delgado Almandoz JE, Crandall BM, Scholz JM, Fease JL, Anderson RE, Kakkodhayan Y, et al. Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device. J Neurointerv Surg. (2013) 5:iii3–10. doi: 10.1136/neurintsurg-2012-010582

22. Kayan Y, Delgado Almandoz JE, Fease JL, Tran K, Milner AM, Scholz JM. Incidence of delayed ipsilateral intraparenchymal hemorrhage after stent-assisted coiling of intracranial aneurysms in a high-volume single center. Neuroradiology. (2016) 58:261–6. doi: 10.1007/s00234-015-1624-3

23. Bhogal P, Bleise C, Chudyk J, Lylyk I, Perez N, Henkes H, et al. The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapy. J Int Med Res. (2020) 48:300060519879580. doi: 10.1177/0300060519879580

24. Manning NW, Cheung A, Phillips TJ, Wenderoth JD. Pipeline shield with single antiplatelet therapy in aneurysmal subarachnoid haemorrhage: multicentre experience. J Neurointerv Surg. (2019) 11:694–8. doi: 10.1136/neurintsurg-2018-014363

25. Aguilar-Perez M, Hellstern V, AlMatter M, Wendl C, Bäzner H, Ganslandt O, et al. The p48 flow modulation device with hydrophilic polymer coating (HPC) for the treatment of acutely ruptured aneurysms: early clinical experience using single antiplatelet therapy. Cardiovasc Intervent Radiol. (2020) 43:740–8. doi: 10.1007/s00270-020-02418-4

Conflict of Interest: MA-P and VH serve as proctors and consultants for phenoX. HH is a co-founder and share-holder of phenoX and femtoS.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hellstern, Aguilar-Pérez, Henkes, Serna-Candel, Wendl, Bäzner, Ganslandt and Henkes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.